c-Met inhibitor

Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer

Retrieved on: 
Thursday, June 17, 2021
Health sciences, Health, Drugs, Breakthrough therapy, Orphan drugs, Protein kinase inhibitors, Infectious causes of cancer, c-Met inhibitor, Cancer research, Stomach cancer, ALK inhibitor, ROS1

We are pleased to receive this designation for TPX-0022 as we work to develop it as a potentially differentiated option for patients affected by MET-driven gastric cancer.

Key Points: 
  • We are pleased to receive this designation for TPX-0022 as we work to develop it as a potentially differentiated option for patients affected by MET-driven gastric cancer.
  • There are currently no approved MET inhibitors for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma.
  • Orphan Drug Designation is granted by the FDA to assist in the development of drug candidates that may offer therapeutic benefits for diseases with a prevalence of fewer than 200,000 patients annually.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Hepatocyte Growth Factor Pipeline Report, H2 2020 Edition - ResearchAndMarkets.com

Retrieved on: 
Monday, April 26, 2021
Health, Pharmaceutical, Branches of biology, Biology, Cytokines, Hepatocyte growth factor, HGF, Growth factor, Wound healing, Myogenesis, c-Met inhibitor, Helixmith

b'The "Hepatocyte Growth Factor - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\n\'Hepatocyte Growth Factor - Pipeline Review, H2 2020\'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules.\nHepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor.

Key Points: 
  • b'The "Hepatocyte Growth Factor - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\n\'Hepatocyte Growth Factor - Pipeline Review, H2 2020\'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules.\nHepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor.
  • It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing.
  • In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.\nThe report \'Hepatocyte Growth Factor - Pipeline Review, H2 2020\' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.\nIt also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects.
  • Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 5, 3, 4 and 3 respectively.\nThe report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities\n'